Defining optimal triage strategies for hrHPV screen–positive women - An evaluation of HPV 16/18 genotyping, cytology, and p16/Ki-67 cytoimmunochemistry

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 11, 2017, Pages 1629-1635

  Stanczuk, Grazyna A ^a   Baxter, Gwen J ^a   Currie, Heather ^a   Forson, William ^a   Lawrence, James R ^a   Cuschieri, Kate ^b   Wilson, Allan ^c   Patterson, Lynne ^c   Govan, Lynn ^c   Black, Janice ^c   Palmer, Tim ^d   Arbyn, Marc ^e  

^a DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c MONKLANDS HOSPITAL   (United Kingdom)

^d NHS HIGHLAND   (United Kingdom)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ARTICLE; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VAGINA; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; GENETICS; GENOTYPING TECHNIQUE; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; LIQUID BIOPSY; MIDDLE AGED; PROCEDURES; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CROSS-SECTIONAL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LIQUID BIOPSY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 85034074540     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-17-0534     Document Type: Article

References (37)

1. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine 2012;30 Suppl 5:F88–F99.
2. von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the Supplements on HPV Screening and Vaccination (Review) Papillomavirus Research 2015;1:22–31.
3. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516–20.
4. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147–72.
5. Luttmer R, De Strooper LM, Steenbergen RD, Berkhof J, Snijders PJ, Heideman DA, et al. Management of high-risk HPV-positive women for detection of cervical (pre)cancer. Expert Rev Mol Diagn 2016;16:961–74.
6. Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol 2016;76 Suppl 1:S49–55.
7. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130:602–10.
8. Wright TC Jr, Stoler MH, Behrens CM, Sharma A, Sharma K, Apple R. Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial. Int J Cancer 2014;134:1835–43.
9. Palmer TJ, McFadden M, Pollock KG, Kavanagh K, Cuschieri K, Cruickshank M, et al. HPV immunisation and cervical screening–confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br J Cancer 2016;114: 582–9.
10. Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, et al. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer 2015;136:2361–8.
11. Luttmer R, Berkhof J, Dijkstra MG, van Kemenade FJ, Snijders PJ, Heideman DA, et al. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women. J Clin Virol 2015;67:59–66.
12. Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14:168–76.
13. Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN, Stiemerling E, et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst 2015; 107:djv257.
14. Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, et al. The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer 2015;136:2741–51.
15. Chatzistamatiou K, Moysiadis T, Moschaki V, Panteleris N, Agorastos T. Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening. Gynecol Oncol 2016;142:120–7.
16. Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol 2015;53: 52–9.
17. von Knebel Doeberitz M, Reuschenbach M, Schmidt D, Bergeron C. Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics 2012;9:149–63.
18. Roelens J, Reuschenbach M, von Knebel-Doeberitz M, Wentzensen N, Bergeron C, Arbyn M. p16INK4a immunocytochemistry versus HPV testing for triage of women with minor cytological abnormalities: a systematic review and meta-analysis. Cancer 2012;120:294–307.
19. Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open 2016;6:e010660.
20. Smith JHF, Patnick J. Achievable standards, benchmarks for reporting and criteria for conducting cervical cytopathology. Second edition. Sheffield, United Kingdom: NHS Cancers Screening Programme; 2013. Available from: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp01.html.
21. In: Luesley D, Leeson S(editors). 2010. Colposcopy and programme management, 2nd ed. NHS Cancers Screening Programme, Sheffield, United Kingdom. Available from: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.html.
22. Hirschowitz L. Histopathology reporting in cervical screening—an integrated approach. Second edition. Sheffield, United Kingdom: NHS Cancers Screening Programme; 2012. Available from: http://www.cancerscreening.nhs.uk/cervical/publications/cc-04.html.
23. Arbyn M, Xu L, Verdoodt F, Cuzick J, Szarewski A, Belinson J, et al. Genotyping for HPV16 and HPV18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med 2017;166:118–27.
24. Benoy IH, Vanden Broeck D, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, et al. Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol 2011;205:569.
25. Tang NS, Tang ML, Chan IS. On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 2003;22:1217–33.
26. Arbyn M, Snijders PJ, Meijer CJ, Berkhof H, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect 2015;21:817–26.
27. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol 2015;125:330–7.
28. Arbyn M, Roelens J, Martin-Hirsch P, Leeson S, Wentzensen N. Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. Br J Cancer 2011;105:877–80.
29. Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer 2015;51:2375–85.
30. Zhang SK, Ci PW, Velicer C, Kang LN, Liu B, Cui JF, et al. Comparison of HPV genotypes and viral load between different sites of genital tract: the significance for cervical cancer screening. Cancer Epidemiol 2014;38: 168–73.
31. De Strooper LM, Verhoef VM, Berkhof J, Hesselink AT, de Bruin HM, van Kemenade FJ, et al. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol 2016;141:341–7.
32. Hesselink AT, Heideman DA, Steenbergen RD, Gök M, van Kemenade FJ, Wilting SM, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 2014;135:880–6.
33. Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M, et al. VALGENT: A protocol for clinical validation of human papillomavirus assays. J Clin Virol 2016;76 Suppl 1:S14–21.
34. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15:172–83.
35. Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer 2016;138:2745–51.
36. Verhelst S, Poppe WA, Bogers JJ, Depuydt CE. Serial measurement of type-specific human papillomavirus load enables classification of cervical intraepithelial neoplasia lesions according to occurring human papillomavirus-induced pathway. Eur J Cancer Prev 2017;26:156–64.
37. Bhatia R, Kavanagh K, Cubie HA, Serrano I, Wennington H, Hopkins M, et al. Use of HPV testing for cervical screening in vaccinated women–Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study. Int J Cancer 2016;138:2922–31.